Cure SMA Publishes Paper in Partnership with NeurologyLive on Impact of COVID-19



Cure SMA has published a paper, titled “Spinal Muscular Atrophy and COVID-19: Guidance and Resources for Providers,” in partnership with NeurologyLive.

The article highlights findings from a recent survey conducted by Cure SMA to measure the impact of COVID-19 on the spinal muscular atrophy (SMA) patient and family community. As of June 1, 2020, 1,513 individuals completed the survey. The findings revealed that the pandemic has impacted access to clinics (42%), timely access to SMA treatment (20%), and household finances (66%). Exposure to COVID-19, or having symptoms of COVID-19, was reported to have impacted 5% of respondents.

Since COVID-19 is easily transmissible, members of the SMA community are encouraged to practice infection control and isolation. However, SMA treatments are essential procedures and dosing should not be delayed. The article offers guidance and resources to healthcare providers, encouraging the timely administration of treatment and other care needs.

Cure SMA would like to thank the entire SMA community for their contribution to this study. Individuals living with SMA, their families, and healthcare providers are encouraged to visit the Coronavirus (COVID-19) Information Center to access the latest information, community resources, and support programs offered by Cure SMA.

Do you like what you're reading?

Help make a difference in the lives of people affected by spinal muscular atrophy.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top